Overview

Effect of Venglustat in Patients With Renal Impairment

Status:
Completed
Trial end date:
2019-02-27
Target enrollment:
Participant gender:
Summary
Primary Objective: To study the effect of mild, moderate and severe renal impairment on the pharmacokinetics (PK) of Venglustat following a single dose. Secondary Objective: To assess the tolerability of Venglustat given as a single dose in subjects with mild, moderate and severe renal impairment in comparison with matched subjects with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Genzyme, a Sanofi Company